WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
MedPage Today on MSN
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...
Adding apalutamide to ADT in the adjuvant and neoadjuvant settings improves outcomes in prostate cancer patients undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results